A Study of CLR325 in Chronic Stable Heart Failure Patients.

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Stable Heart Failure

In brief

The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.

Key facts

Study ID

NCT02696967

Run by

Novartis Pharmaceuticals

People needed

26

Starts

2016-05-17

Expected to finish

2019-01-14

Last updated by the study team

2021-01-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Investigative Site — Chicago, Illinois, United States
• Novartis Investigative Site — St Louis, Missouri, United States
• Novartis Investigative Site — Cleveland, Ohio, United States
• Novartis Investigative Site — Philadelphia, Pennsylvania, United States
• Novartis Investigative Site — Houston, Texas, United States
• Novartis Investigative Site — Tacoma, Washington, United States
• Novartis Investigative Site — Aalst, Belgium
• Novartis Investigative Site — Regensburg, Bavaria, Germany
• Novartis Investigative Site — Greifswald, Germany
• Novartis Investigative Site — Amsterdam, Netherlands
• Novartis Investigative Site — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.